Skip to main content
. Author manuscript; available in PMC: 2016 Jun 15.
Published in final edited form as: Cancer Res. 2015 Apr 13;75(12):2489–2500. doi: 10.1158/0008-5472.CAN-14-3167

Figure 5. In vivo combination of AZD9291 and selumetinib can overcome acquired resistance to AZD9291 in mutant EGFR trangenic models of lung cancer.

Figure 5

(A) MR images of lungs from tumour-bearing EGFRL858R + T790M transgenic mice pretreatment, after treatment with AZD9291 for 6–20 weeks (W) until progressive disease, and subsequently with the combination of AZD9291/selumetinib for 4–8 weeks. (B) MR images of lung from tumour-bearing EGFRL858R + T790M mice pre- and post- treatment with selumetinib for 1–2 weeks (1W/2W). Combo, AZD9291/selumetinib; H, heart; arrow denotes tumour. (C) MR images of lung from a tumour-bearing EGFRL858R transgenic mouse pretreatment, after treatment with AZD9291 for 6–12 weeks (W) until disease progression, and subsequently with the combination of AZD9291/selumetinib for 3 weeks (3W). *Pretreatment images for mouse #461 and #463 were obtained after these mice received 4 weeks of low dose (1–2.5mg/kg) AZD9291 with no response, before being switched to 5mg/kg dosing.